INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34701, 0, 'Buprenorphine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34702, 0, 'Cabotegravir', 'Depressive Disorder', 'Depressive disorders (including depressed mood, depression, altered mood, mood swings) have been reported with oral cabotegravir.  Depressive disorders (including depressed mood, depression, major depression, altered mood, mood swings, dysphoria, negative thoughts, suicidal ideation/attempt) have been reported with IM cabotegravir-rilpivirine or the individual drug products.  Patients with severe depressive symptoms should be evaluated promptly.  Caution should be used in patients with a history of depression or other psychiatric conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34703, 0, 'Cabotegravir', 'Liver Failure', 'Hepatotoxicity has been reported in patients taking cabotegravir with or without known preexisting hepatic disease or identifiable risk factors.  Patients with underlying liver disease or marked transaminase elevations prior to therapy may be at increased risk for worsening or development of transaminase elevations.  Monitoring of liver chemistries is recommended and cabotegravir should be discontinued if hepatotoxicity is suspected.  Cabotegravir has not been studied in patients with severe liver dysfunction (Child-Pugh C); caution is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34704, 0, 'Cabotegravir', 'Kidney Diseases', 'No dose adjustment of IM or oral cabotegravir is required in patients with mild to moderate or mild to severe renal dysfunction, respectively.  Cabotegravir has not been studied in patients with ESRD not on dialysis; caution is recommended.  IM cabotegravir should be used with caution and with increased monitoring for side effects in patients with severe renal dysfunction or ESRD.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34705, 0, 'Calcifediol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34706, 0, 'Calcifediol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34707, 0, 'Calcifediol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34708, 0, 'Calcifediol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34709, 0, 'Butorphanol', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34710, 0, 'Butorphanol', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34711, 0, 'Butorphanol', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34712, 0, 'Butorphanol', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34713, 0, 'Butorphanol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34714, 0, 'Butorphanol', 'Myocardial Infarction', 'Opiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous administration.  Data are available for pentazocine and butorphanol.  Therapy with opiate partial agonists should be administered cautiously and only if the benefit justifies the risk in patients with acute myocardial infarction (especially if accompanied by hypertension or left ventricular failure) or coronary insufficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34715, 0, 'Butorphanol', 'Substance-Related Disorders', 'Opiate partial agonists have the potential to cause dependence and abuse, particularly in patients with a history of drug abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use, and abrupt cessation or a significant reduction in dosage may precipitate withdrawal symptoms.  Because of their opiate antagonistic effect, withdrawal symptoms may also occur if opiate partial agonists are administered to patients with an opiate dependence or in whom substantial amounts of narcotics have recently been administered.  Therapy with opiate partial agonists is not recommended in patients who are physically dependent on narcotics.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate partial agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34716, 0, 'Butorphanol', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate partial agonists can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Unless mechanical ventilation is provided, extreme caution is advised when opiate partial agonists are given to patients head injury, intracranial lesions, or a preexisting elevated CSF pressure.  Also, clinicians treating such patients should be aware that opiate partial agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34717, 0, 'Butorphanol', 'Respiratory Insufficiency', 'Opiate partial agonists may produce respiratory depression by decreasing respiratory drive and increasing airway resistance.  A "ceiling effect" has been noted for these agents, and increasing doses do not produce proportional or further respiratory depression.  However, the duration of effect is prolonged.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate partial agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS or respiratory depression; acute alcohol intoxication; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate partial agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression.  However, in the case of buprenorphine, naloxone may not be effective due to buprenorphine''s slow rate of dissociation from mu receptors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34718, 0, 'Butorphanol', 'Hypertension', 'Butorphanol may increase blood pressure and rarely causes severe hypertension.  Therapy with butorphanol should be administered cautiously in hypertensive patients, particularly when given before surgery or anesthesia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34719, 0, 'Butorphanol', 'Hypotension', 'Butorphanol may rarely induce vasodilation and hypotension with syncope during the first hour following intranasal administration, particularly in patients with a history of similar reactions to opioid analgesic agents.  Therapy with butorphanol should be administered cautiously in patients with circulatory shock, hypovolemia, or a predisposition to hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34720, 0, 'Butorphanol', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34721, 0, 'Butorphanol', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34722, 0, 'Butorphanol', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34723, 0, 'Butorphanol', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34724, 0, 'Butorphanol', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34725, 0, 'Butorphanol', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34726, 15638, 'Calcitriol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34727, 15638, 'Calcitriol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34728, 15638, 'Calcitriol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34729, 15638, 'Calcitriol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34730, 15638, 'Calcitriol', 'Diseases requiring dialysis', 'Calcitriol increases inorganic phosphate levels in serum and caution should be used in patients with renal impairment to maintain adequate phosphorus levels and avoid ectopic calcification.  A non-aluminum phosphate-binding compound and a low phosphate diet should be used to control serum phosphorus levels in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34731, 15638, 'Calcitriol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34732, 15654, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34733, 15658, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34734, 15659, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34735, 25461, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34736, 29077, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34737, 1854, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34738, 1877, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34739, 15624, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34740, 15646, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34741, 15649, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34742, 15670, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34743, 15883, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34744, 23997, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34745, 24230, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34746, 24308, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34747, 28880, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34748, 1854, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34749, 1877, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34750, 15624, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34751, 15646, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34752, 15649, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34753, 15670, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34754, 15883, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34755, 23997, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34756, 24230, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34757, 24308, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34758, 28880, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34759, 1854, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34760, 1877, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34761, 15624, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34762, 15646, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34763, 15649, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34764, 15670, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34765, 15883, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34766, 23997, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34767, 24230, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34768, 24308, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34769, 28880, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34770, 1854, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34771, 1877, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34772, 15624, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34773, 15646, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34774, 15649, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34775, 15670, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34776, 15883, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34777, 23997, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34778, 24230, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34779, 24308, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34780, 28880, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34781, 1854, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34782, 1877, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34783, 15624, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34784, 15646, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34785, 15649, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34786, 15670, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34787, 15883, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34788, 23997, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34789, 24230, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34790, 24308, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34791, 28880, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34792, 13907, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34793, 20565, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34794, 20566, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34795, 30662, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34796, 32403, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34797, 13907, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34798, 20565, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34799, 20566, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34800, 30662, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '', 'DDInter', 0);
